Abstract
Since its emergence, the COVID-19 pandemic has been ravaging the medical and economic sectors even with the significant vaccination advances. In severe presentations, the disease of SARS-CoV-2 can manifest with life-threatening thromboembolic and multi-organ repercussions provoking notable morbidity and mortality. The pathogenesis of such burdensome forms has been under extensive investigation and is attributed to a state of immune dysfunction and hyperinflammation. In light of these extraordinary circumstances, research efforts have focused on investigating and repurposing previously available agents that target the inflammatory and hematological cascades. Aspirin, due to its well-known properties and multiple molecular targets, and ought to its extensive clinical use, has been perceived as a potential therapeutic agent for COVID-19. Aspirin acts at multiple cellular targets to achieve its anti-inflammatory and anti-platelet effects. Although initial promising clinical data describing aspirin role in COVID-19 has appeared, evidence supporting its use remains fragile and premature. This review explores the notion of repurposing aspirin in COVID-19 infection. It delves into aspirin as a molecule, along with its pharmacology and clinical applications. It also reviews the current high-quality clinical evidence highlighting the role of aspirin in SARS-CoV-2 infection.
Highlights
The latest pandemic caused by the novel SARS-CoV-2 virus has led to the emergence of coronavirus disease 2019 termed COVID-19
This study only looked at inpatients and excluded those on chronic aspirin therapy
While the scientific community merged efforts to obtain the vaccine at an unpreceded velocity, the search for a therapeutic agent is still ongoing
Summary
The latest pandemic caused by the novel SARS-CoV-2 virus has led to the emergence of coronavirus disease 2019 termed COVID-19. A high rate of coagulopathy has been described in patients infected with COVID-19, suggesting a critical COVID-19 induced thromboembolic event Such events are major cardiovascular complications and are associated with increased mortality (Zareef et al, 2020; Zhou et al, 2020; Aktaa et al, 2021). Even with the large-scale global vaccination programs, the virus has attained several remarkable mutations and produced new variants such as B.1.1.7, P.1, B.1.351, B.1.427, P.3, B.1.429, B.1.526, and B.1.617.2 (Baden et al, 2021; Chookajorn et al, 2021; Vasireddy et al, 2021; Voysey et al, 2021) This is problematic as emerging variants might acquire the ability to transmit rapidly, and cause more severe disease, while escaping the host immune system (Vasireddy et al, 2021). This paper discusses the potential therapeutic role of aspirin in COVID-19 disease through dissecting its pharmacology, cellular targets, clinical uses, as well as the current high quality clinical evidence
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
